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Abstract
Background: Alzheimer’s disease (AD) is the most common cause of dementia in the elderly. The possibility of
disease-modifying strategies has evoked a need for early and accurate diagnosis. To improve the accuracy of the
clinical diagnosis of AD, biomarkers like cerebrospinal fluid (CSF) and neuroimaging techniques like magnetic
resonance imaging (MRI) and positron emission tomography (PET) have been incorporated into the diagnostic
guidelines of AD.
Case presentation: In this case report we outline in reference to one of our patients with presenile dementia the
current approaches to the diagnosis of AD. The patient was a 59-year old woman presenting with progressive
memory decline. CSF-Aβ42 was normal while P-tau was slightly increased. FDG-PET indicated a pattern typical for
AD, amyloid-PET showed an extensive global amyloid load, and tau-PET depicted a pronounced hippocampal tracer
accumulation. The MRI scan was rated as normal at routine diagnostics, however quantitative volumetric analysis
revealed significant atrophy especially of the parietal lobe. The combination of biomarkers and neuroimaging
techniques was therefore suggestive of an underlying AD pathology.
Conclusions: To enable early and accurate diagnosis of AD and thereby also patient recruitment for anti-tau or
anti-β-amyloid therapeutic trials, a combination of biomarkers and neuroimaging techniques seems useful.
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Background
Alzheimer’s disease (AD) is the most common cause of
dementia and is estimated to affect 106.8 million people
worldwide by the year 2050 [1]. It is clinically characte-
rized by progressive memory and language impairment,
functional and behavioural disturbances and visuospatial
deficits [2]. A definite diagnosis of AD still relies on post-
mortem histopathological detection of intracellular neuro-
fibrillary tangles and extracellular amyloid plaques [3]. It
is widely acknowledged that histopathological changes
start years before clinical manifestation of the disease [4].
As first disease modifying therapies are approaching early
and accurate diagnosis of AD becomes increasingly
important [5]. Therefore the National Institute on Aging
and the Alzheimer’s Association have revised the criteria
for the diagnosis of AD [6]. To assess the probability of an
underlying AD pathology biomarkers of the disease and
neuroimaging techniques have been incorporated into the
diagnostic guidelines of AD. Here we present an exem-
plary case of presenile dementia based on which we
discuss the approaches to the diagnosis of AD.
Case presentation
A 59 year old retired attorney, with 18 years of educa-
tion presented with a three year history of progressive
memory decline. For about one year she hadn’t been
able to do the shopping or the cooking. No behavioural
changes, language impairment, severe fluctuations of
attention and alertness, recurrent visual hallucinations
or history of repetitive brain trauma were reported.
Family history was positive, her mother as well as an
uncle had developed late-onset dementia.
The Mini-Mental-State Examination which had been
performed three years ago because of subjective memory
impairment had been rated as normal. For neuropsy-
chological testing we applied the CERAD plus battery
* Correspondence: sonja.schoenecker@med.uni-muenchen.de
1Department of Neurology, Ludwig-Maximilians University, Munich, Germany
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Schönecker et al. BMC Neurology  (2016) 16:131 
DOI 10.1186/s12883-016-0647-7
additionally including Trail Making Test A and B as well
as verbal fluency tests. The scores of almost all domains
of the CERAD plus battery were at least −1.37 standard
deviations below the age- and education-adjusted norm
values. She scored 24 out of 30 points in the Mini-
Mental-State Examination. Naming (Boston-Naming-test)
was intact whereas phonemic verbal fluency was slightly
(11 words in 1 min) and semantic fluency (9 words in
1 min) was highly reduced. Memory was highly impaired.
She displayed intrusions and showed a reduced perform-
ance of word list recall and recognition. Constructional
practice was impaired as well. Results of the Trail-Making
Test showed reduced visual attention as well as reduced
speed of processing. Cognitive flexibility measured by
Trail-Making-Test B was also poor.
At first presentation the neurological examination was
normal. In particular no manifest or latent paresis and no
sensory deficit could be detected. Deep tendon reflexes
were mildly hypoactive without any pathological reflexes.
Cranial nerves were also intact. There was no evidence of
extrapyramidal features.
Laboratory tests for metabolic causes of dementia, for
example for vitamin B12, thyroid, liver and renal function,
thiamine level and folate were within the normal range.
P-tau (66 pg/ml, N < 61 pg/ml) in cerebrospinal fluid (CSF)
was only slightly increased, whereas total Tau (293 pg/ml,
N < 500 pg/ml) and Aβ42 (1171 pg/ml, N > 500 pg/ml) were
normal. All other CSF parameters were within the normal
range.
The MRI scan which had been performed three years
ago as well as the MRI scan at first presentation were
interpreted as normal at visual inspection. Especially no
sign of global or regional atrophy could be detected. How-
ever, atlas-based volumetric MRI analysis [7, 8] showed a
significant reduction especially of temporal and parietal
lobe volumes. Z-scores for the hippocampal and parietal
volumes compared to healthy controls were −2.9 and −4.2
respectively (Fig. 1).
Moreover, a quantitative analysis based on voxel-wise
z-score analysis of patient grey matter segments and grey
matter segments from an age and sex-matched control
sample after bias correction and spatial normalization in a
common standard space following an established method
[9] showed a slight asymmetry with more pronounced
atrophy of rightsided parietotemporal cortical areas (voxel
based grey matter reduction z > −1.96) (Fig. 2). It has to be
noted that for the quantitative analysis, data of the com-
parison group came from another MRI scanner than the
scan of the patient. Acquisition parameters were harmo-
nized between scanners to accommodate possible scanner
effects.
Fluorodeoxyglucose-PET (FDG-PET) showed an asym-
metric reduction of brain glucose metabolism of parietal
and temporal cortical areas with a more pronounced
reduction of glucose metabolism in the right hemisphere.
In addition glucose metabolism of the posterior cingulate
cortex was significantly reduced (Fig. 2).
The patient underwent a florbetaben-PET (FBB-PET)
scan which showed extensive FBB retention that was
greater in parietotemporal, frontal and posterior cingu-
late/precuneus cortex and less pronounced in the occipital
cortex. Basal ganglia were also slightly affected (Fig. 3).
The tau-PET scan with THK-5351 on the other hand
showed high tracer retention in both hippocampi as well
as moderately increased tracer retention in parietotem-
poral cortical areas. There was no elevated tracer reten-
tion in other cortical areas (Fig. 3).
Conclusions
As our patient presented with a three year history of
cognitive decline that interfered with activities of daily
living and scored low in almost all domains of the CERAD
plus battery a clinical diagnosis of AD was made [6].
Because of the presenile age at onset and the positive
family history a monogenic form of AD might be possible.
Genetic testing could have excluded conditions mimicking
sporadic AD-like dementia. Our patient however refused
genetic testing. Sensitivity and specificity of the clinical
diagnosis of AD compared to post-mortem histopatho-
logical diagnosis ranges from 70.9 to 87.3 % and from 44.3
to 70.8 % respectively [10]. The combination of biomarkers
and neuroimaging techniques was suggestive of an under-
lying AD pathology. In absence of a neuropathological
Fig. 1 Volumetric MRI analysis of our patient’s (dark arrow)
hippocampus and parietal lobe compared to AD patients
and age-matched healthy controls after intracranial-volume
correction. Z-scores of hippocampal and parietal lobe volume
compared to healthy controls were −2.9 and −4.2 respectively.
Our patient’s datapoint lay within the 95 % confidence region of
Alzheimer’s disease and outside the 95 % confidence region of
healthy controls and was therefore automatically assigned to the
Alzheimer’s disease group
Schönecker et al. BMC Neurology  (2016) 16:131 Page 2 of 8
confirmation of AD pathology, a definite diagnosis of AD,
however, was not possible. The most important alternative
diagnosis in a case of presenile dementia are dementia with
Lewy bodies (DLB), frontotemporal dementia with memory
impairment (FTD) and chronic traumatic encephalopathy
(CTE). As our patient had no pronounced variation in
attention and alertness, reported no recurrent visual hallu-
cinations and displayed no features of parkinsonism the
core features of DLB were not fulfilled [11]. Furthermore
no progressive deterioration of personality or social com-
portment was reported and there was no evidence of
progressive language impairment. Therefore there was no
clinical evidence for behavioural variant frontotemporal
dementia [12] or primary progressive aphasia [13]. As there
was no history of recurrent impacts to the head or body,
CTE seemed unlikely as well [14]. Table 1 summarizes
biomarker and neuroimaging findings in autopsy confirmed
cases of DLB, FTD and CTE. [References in Table 1:
[15–30]]. In the following the current diagnostic ap-
proaches used in the diagnosis of AD are illustrated with
reference to our 59-year old patient.
Neuropsychological testing is commonly used as an
aid in diagnosing AD. In our patient the scores of almost
all domains of the CERAD plus battery were well below
average. Memory was most severely affected. As the
earliest pathological changes in AD occur in medial
temporal lobe structures [31] episodic memory is usually
the first cognitive ability to decline, typically followed,
like in our case by additional deficits in language and
semantic knowledge, executive functions, working mem-
ory, attention and visuospatial abilities [32].
Results of laboratory testing for example for vitamin B12,
thyroid function, thiamine level and folate, were within the
normal range. Laboratory testing should be performed in
every AD patient to rule out metabolic causes of dementia.
CSF did not suggest malignancy, neuroinflammation or
infection. P-tau that reflects the intensity of neuronal de-
generation was slightly increased. Interestingly, although
amyloid-PET revealed an extensive global amyloid load,
CSF-Aβ42 on the other hand was normal. It has been
shown that amyloid load at autopsy of AD patients is
inversely correlated to CSF-Aβ42 whereas tau load is
positively correlated to CSF P-tau and total tau [33]. Yet
although CSF and amyloid-PET measurements of Aβ42
are consistent in the majority of patients a dissociation
Fig. 3 Aβ and tau imaging with FBB (top) and THK-5351 (bottom)
of our 59 year old patient with Alzheimer’s disease. FBB and
THK-5351 binding patterns demonstrate the different distributions
of Aβ and tau deposits in the brain of our Alzheimer’s disease
patient. FBB-PET scan revealed a massive global amyloid load
with a pronounced FBB retention in parietotemporal, frontal
and posterior cingulate/precuneal cortices. In contrast THK-5351
retention was markedly elevated in the hippocampus, whereas
onlya slightly increased THK-5351 retention was observed in
parietotemporal cortical areas
Fig. 2 Positron emission tomography of the brain with F-18-labeled
fluorodeoxyglucose (FDG-PET) and three-dimensional surface
representation of brain regions with grey matter reduction of
our 59-year-old AD patient compared to 18 healthy controls. Top:
regional uptake of radiolabelled glucose; the left lateral, left medial
and right lateral views of the brain are presented. Middle: regional
metabolic reduction compared to age-matched healthy controls
according to the methodology of Minoshima et al. [53]. There is an
asymmetric metabolic reduction parietotemporal and in posterior
cingulate cortex with a more pronounced reduction of glucose
metabolism in the right hemisphere. Bottom: color-coded brain
matter reduction. Z-values of grey matter reduction are projected on
T1-weighted, averaged brain surface of healthy control subjects
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Table 1 Summary of biomarker and neuroimaging findings in autopsy confirmed DLB, FTD and CTE cases
Population CSF biomarker/Ligand Major findings
CSF
Clark et al.(15] 60 AD, 10 FTD, 3 DLB total Tau, Aβ42 higher total tau in AD compared to FTD and DLB
Aβ42 reduced in AD compared to FTD but not compared to DLB
Slaets et al. [16] 30 AD,
13 DLB with SP,
5 DLB without SP
30 AD,
9 DLB with NFT, 9 DLB
without NFT
P-Tau, total Tau, Aβ42 Aβ42 reduced in AD and DLB with SP compared to DLB without SP
no difference in Aβ42 levels of AD and DLB with SP patients
P-Tau, total Tau, Aβ42 P-Tau higher in AD compared to DLB with and without NFT
no difference in P-Tau levels of DLB with and without NFT
no difference of total Tau between the DLB subgroups and AD
Koopmann et al. [17] 95 AD, 18 DLB, 10 FTD P-Tau, total Tau, Aβ42 P-Tau cut-off for differentiating AD from FTD 35.3 pg/ml,
from DLB 52.8 pg/ml
total Tau level: AD > DLB > FTD
Aβ42 level: AD < DLB = FTD
Bian et al. [18] AD 19, FTD 30 total Tau, Aβ42 total Tau and tau/Aβ42 ratio lower in FTD than in AD
Toledo et al. [19] 71 AD, 29 FTD P-Tau, total Tau, Aβ42 high sensitivity and specificity of combined CSF biomarkers
in classifying AD against FTD
P-Tau and total Tau higher in AD compared to FTD
Aβ42 lower in AD compared to FTD
MRI
Vemuri et al. [20] 48 AD, 47 FTD, 20 DLB atrophy pattern in AD: temporoparietal association cortices
and medial temporal lobe
FTD: frontal and temporal lobes
DLB: bilateral amygdalae, dorsal midbrain, inferior temporal lobe
Rabinovici et al. [21] 11 AD, 18 FTD atrophy in AD: posterior temporoparietal and occipital atrophy
atrophy in FTD: medial prefrontal and medial temporal
cortex, insula, hippocampus, amygdala
Burton et al. [22] 11 AD, 23 DLB pronounced medial temporal lobe atrophy in AD compared to
DLB patients
Kantarci et al. [23] 2 AD, 3DLB more pronounced hippocampal atrophy in AD compared to DLB
McKee et al. [24] 1 CTE generalized cortical atrophy, enlargement of ventricles, cavum
septum pellucidum
FDG-PET
Minoshima et al. [25] 10 AD, 4 DLB AD and DLB: hypometabolism in posterior cingulate,
parietotemporal and frontal association cortices
additional occipital hypometabolism in DLB
Albin et al. [26] 3 AD-DLB, 3 DLB compared to AD additional hypometabolism in occipital
association and primary visual cortex
Kantarci et al. [23] 2 AD, 3 DLB low occipital FDG-uptake in 1 AD patient and all DLB patients
Foster et al. [27] 31 AD, 14 FTD AD: temporoparietal and posterior cingulate hypometablism
FTD: frontal, anterior cingulate and anterior temporal hypometabolism
Amyloid-PET
Kantarci et al. [23] 2 AD, 3 DLB PiB high global cortical PiB retention in one AD patient, low
global cortical PiB in the other
2 DLB patients with borderline PiB retention, 1 DLB
patient with high PiB retention
Bacskai et al. [28] 1 DLB PiB tracer uptake in posterior cingulate, precuneus, posterior parietal,
middle and inferior temporal, insular, lateral and orbital frontal cortices
Rabinovici et al. [29] 3 AD, 7 FTD PiB higher PiB retention in AD compared to FTD
better classification accuracy of PiB-PET compared to FDG-PET
Tau-PET
Ghetti et al. [30] 1 FTD T807 elevated tracer uptake in anterior, temporal and parietal cortex as
well as basal ganglia
CSF cerebrospinal fluid, AD Alzheimer’s disease, FTD frontotemporal dementia, DLB dementia with lewy bodies, CTE chronic traumatic encephalopathy, SP senile
plaque, NFT neurofibrillary tangles, MRI magnetic resonance imaging, PET positron emission tomography, FDG fluorodeoxyglucose
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between Aβ42 measurements is not uncommon [34].
Especially the combination of CSF biomarkers may in-
crease diagnostic certainty of AD pathology. Yet, as CSF
biomarkers do not change during the clinical phase of
AD, they cannot be used as markers of disease progression
[35]. In comparison to AD patients, DLB and FTD
patients present significantly lower P-tau and total tau
levels [17]. There is however some overlap in CSF P-tau
and total tau between AD, DLB and FTD patients. Aβ42 is
generally decreased in DLB. Most studies could not define
valuable CSF Aβ42 cut-off scores for differentiation of
DLB from AD [36]. CSF Aβ42 levels of FTD patients on
the other hand are significantly higher compared to AD
patients [18]. The combination of CSF P-tau, total tau and
Aβ42 has shown high diagnostic sensitivity and specificity
in distinguishing AD from DLB and FTD patients. In CTE
one would expect normal CSF Aβ42 levels and an elevated
P-tau/total tau ratio [14]. Large biomarker studies on
autopsy confirmed CTE cases however are lacking. AS
CSF P-tau was only slightly increased while CSF total tau
and Aβ42 were within the normal range, CSF analysis was
not suggestive of an underlying AD pathology in our case.
The MRI scan was interpreted as normal at routine
diagnostics, especially no sign of normal-pressure hydro-
cephalus, cerebrovascular disease, tumours or regional/
global atrophy could be detected. Volumetric MRI analysis
however revealed significant atrophy of the parietal and
temporal lobe, especially of the hippocampus, and may
therefore be useful to obtain rater- independent and
objective results [7, 8]. Comparison of atrophy patterns
can differentiate AD patients with a high sensitivity and
specificity from healthy controls and other dementia syn-
dromes like DLB and FTD [20]. In DLB significant gray
matter loss is detectable in bilateral amygdalae, the middle
temporal lobe as well as the dorsal ponto-mesencephalic
junction area [20]. In FTD patients atrophy is normally
restricted to the frontal and temporal lobes, with relative
sparing of the parietal and occipital lobes. MRI may also
be useful to detect neuropathological changes observed in
CTE like whole brain atrophy or cavum septum pellu-
cidum with occasional fenestration [24]. In our case volu-
metric MRI analysis showed a typical AD atrophy pattern
with pronounced atrophy of the parietal and temporal
lobe, especially the hippocampus, and therefore supported
the diagnosis of AD. In Alzheimer’s disease patients, espe-
cially hippocampal atrophy (Fig. 1) seems to be highly
correlated with episodic memory impairment [37].
In the FDG-PET scan (Fig. 2) the typical AD pattern
consisting of a reduction of cerebral glucose metabolism
in precuneus, posterior cingulate and parietotemporal
association cortices [38] could be detected. In comparison,
DLB patients show an additional significant metabolic
reduction in the occipital cortex, particularly the primary
visual cortex, which distinguishes DLB with a high
sensitivity and specificity from AD patients [25]. FTD on
the other hand causes hypometabolism in the frontal
lobes, the anterior temporal cortex and anterior cingulate
cortex [27]. FDG-PET studies that evaluated glucose
metabolism in subjects with repetitive brain trauma have
shown inconsistent findings [39, 40]. In summary, FDG-
PET clearly supported AD as the most probable diagnosis
in our case. Like structural MRI, FDG-PET represents a
marker of neuronal injury. Retrospective investigations
showed a sensitivity of 84 % and a specificity of 74 % for
FDG-PET in predicting post-mortem AD pathology at
autopsy [41]. FDG-PET thereby outperformed the initial
clinical evaluation. Furthermore, FDG-PET seems to be a
suitable predictor of conversion to AD in patients with
mild cognitive impairment [42].
Amyloid- and tau-Pet represent new diagnostic tools.
To present a definite diagnosis of AD relies on post-
mortem histopathology. Yet these new imaging techniques
permit non-invasive visualization and quantification of the
two histological hallmarks of the disease.
Amyloid-PET showed a characteristic increase of tracer
uptake in cortical regions known to have a high amount
of amyloid burden in AD, i.e. frontal, parietal and lateral
temporal cortex (Fig. 3). DLB patients can show a similar
pattern yet with lower amount of Aβ ligand binding com-
pared with AD patients [43]. FTD patients on the other
hand display low cortical tracer retention such that amyl-
oid PET has shown high accuracy in discriminating AD
from FTD [44, 45]. Variable degrees of diffuse β-amyloid
can be detected in about 47 % of autopsy confirmed CTE
cases [46]. Amyloid-PET may therefore differentiate
between CTE and AD by identifying different amyloid-
deposition patterns. Further studies are needed to deter-
mine the topography of β-amyloid depositions in CTE.
Showing a high amount of tracer uptake in parietotem-
poral, frontal and posterior cingulate/precuneus cortex,
FBB-PET was suggestive for AD in our case. Recent phase
III studies in which the in-vivo uptake of 18-F-labelled
amyloid tracers was compared to post-mortem amyloid
load showed a sensitivity and specificity of 88 to 92 %, and
88 to 100 % respectively for the detection of amyloid de-
posits in AD patients [47–49]. As amyloid deposition
probably represents a very early event in the course of the
disease that occurs years before onset of dementia symp-
toms, amyloid-PET may allow early and even presymp-
tomatic diagnosis [4].
Increased tau-tracer retention could be detected in
parietotemporal cortical areas, especially in the hippocam-
pus (Fig. 3). In contrast to amyloid-PET the sensitivity and
specificity of tau-PET imaging have yet to be determined.
Post-mortem studies have shown that the amount of tau
deposition is highly related to the severity of dementia
[50]. In addition to aiding in the early and differential
diagnosis of Alzheimer’s disease tau-PET may therefore
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serve as a marker of disease progression. Recently, first
experiences with tau-PET in DLB were reported [51]. Tau
deposition is elevated in some cases of DLB, especially in
the inferior temporal region. Tau-PET scans may be
positive in some variants of FTD. A first case report of a
P301L MAPT mutation carrier showing elevated tau
tracer uptake in frontal, anterior temporal and parietal
cortex as well as in basal ganglia has been published [30].
Hitherto a single case report of a patient with a clinical
diagnosis of CTE who underwent tau-PET imaging has
been published [52]. Increased tracer uptake could be
detected in globus pallidus, putamen, hippocampus and
substantia nigra. Because of increased tracer retention in
basal ganglia the detected distribution of tracer retention
seemed more suggestive of progressive supranuclear palsy.
However the patient did not manifest the typical clinical
symptoms of progressive supranuclear palsy. In summary
tau-PET also supported a diagnosis of AD in our case.
Overall, although CSF Aβ42 was normal, the combi-
nation of biomarker and neuroimaging findings in this
case was still suggestive of AD pathology. Table 2 rates
the biomarker and neuroimaging findings of our case
with respect to possible differential diagnosis.
As some of the illustrated diagnostic approaches pro-
vided converging evidence, e.g. CSF P-tau, MRI, FDG-
PET and Tau-PET each indicated an AD typical neuronal
degeneration and thereby provided somewhat redundant
information, the necessity for a diagnostic algorithm be-
comes obvious. A sequential diagnostic process where
widely available diagnostic tools like neuropsychological
testing to establish the diagnosis of a dementia syndrome
and laboratory testing to exclude metabolic causes of
dementia are performed in a first step may be useful. Such
a baseline testing could help to select patients that profit
from further diagnostic work-up. In a second step CSF
examination and structural MRI may be rational, on the
one hand to further exclude potentially treatable causes of
dementia like neuroinflammation or normal pressure
hydrocephalus and on the other hand to obtain evidence
for an AD-related pathological process and AD typical
neuronal degeneration. In patients presenting with an
atypical clinical course or atypically early age of onset the
more expensive nuclear medicine diagnostic techniques
FDG-, amyloid- and tau-PET might be useful to differen-
tiate between AD and important differential diagnoses like
pseudo-dementia or frontotemporal dementia. They may
also serve as markers of disease progression and prog-
nostic markers. Especially tau and amyloid imaging may
furthermore be useful for patient recruitment and serve as
a surrogate marker for monitoring the efficacy of future
anti-tau or anti-amyloid strategies.
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